Baxter Adding $200 Mil. In Critical Care Rx Sales Via ESI Lederle Deal
Executive Summary
Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth
You may also be interested in...
Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order
A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business